MX2023004937A - Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas. - Google Patents

Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas.

Info

Publication number
MX2023004937A
MX2023004937A MX2023004937A MX2023004937A MX2023004937A MX 2023004937 A MX2023004937 A MX 2023004937A MX 2023004937 A MX2023004937 A MX 2023004937A MX 2023004937 A MX2023004937 A MX 2023004937A MX 2023004937 A MX2023004937 A MX 2023004937A
Authority
MX
Mexico
Prior art keywords
compound
formula
solid state
state forms
iii
Prior art date
Application number
MX2023004937A
Other languages
English (en)
Inventor
Hanlan Liu
Jeremy Clinton Wilt
Friedrich Blatter
Giuseppe Lapadula
Original Assignee
Ksq Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ksq Therapeutics Inc filed Critical Ksq Therapeutics Inc
Publication of MX2023004937A publication Critical patent/MX2023004937A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente descripción está relacionada con: a) formas en estado sólido de un compuesto con la Fórmula (I), un compuesto con la Fórmula (II) y un compuesto con la Fórmula (III); b) composiciones farmacéuticas que comprenden una o más formas en estado sólido de un compuesto con la Fórmula (I), un compuesto con la Fórmula (II) y un compuesto con la Fórmula (III) y, opcionalmente, un vehículo o diluyente farmacéuticamente aceptable; c) métodos de tratamiento de tumores o cánceres mediante la administración de una o más formas en estado sólido de un compuesto con la Fórmula (I), un compuesto con la Fórmula (II) y un compuesto con la Fórmula (III) a un sujeto que lo necesite; y d) métodos para la preparación de formas en estado sólido de un compuesto con la Fórmula (I), un compuesto con la Fórmula (II) y un compuesto con la Fórmula (III).
MX2023004937A 2020-10-30 2021-10-28 Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas. MX2023004937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063107765P 2020-10-30 2020-10-30
PCT/US2021/057072 WO2022094096A1 (en) 2020-10-30 2021-10-28 Solid state forms of substituted pyrazolopyrimidines and uses thereof

Publications (1)

Publication Number Publication Date
MX2023004937A true MX2023004937A (es) 2023-05-17

Family

ID=81384285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004937A MX2023004937A (es) 2020-10-30 2021-10-28 Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas.

Country Status (11)

Country Link
US (2) US11718624B2 (es)
EP (1) EP4236958A1 (es)
JP (1) JP2023548148A (es)
KR (1) KR20230098186A (es)
CN (1) CN116615424A (es)
AU (1) AU2021371305A1 (es)
CA (1) CA3196564A1 (es)
IL (1) IL302352A (es)
MX (1) MX2023004937A (es)
TW (1) TW202233621A (es)
WO (1) WO2022094096A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140732A (ko) * 2020-02-14 2022-10-18 케이에스큐 세러퓨틱스 인코포레이티드 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물
AU2022387669A1 (en) * 2021-11-12 2024-05-16 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
CA3235765A1 (en) 2021-11-12 2023-05-19 Jianping Wu Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2023208130A1 (zh) * 2022-04-29 2023-11-02 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
WO1996023899A1 (en) 1995-02-01 1996-08-08 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
CA2267139A1 (en) 1996-10-08 1998-04-16 Ton Logtenberg Methods and means for selecting peptides and proteins having specific affinity for a target
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US7754463B2 (en) 2006-06-20 2010-07-13 Dana-Farber Cancer Institute Inhibitors of USP1 Deubiquitinating Enzyme Complex
US20090062196A1 (en) 2006-10-20 2009-03-05 D Andrea Alan Compositions and methods of treating cancer
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
JP2010532312A (ja) * 2007-01-30 2010-10-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド １−ｈ−ピラゾロ（３，４ｂ）ピリミジン誘導体および有糸分裂キナーゼの調節剤としてのその使用
KR101701109B1 (ko) 2007-10-05 2017-02-13 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
GB0917934D0 (en) 2009-10-13 2009-11-25 Syngenta Ltd Herbicidal compounds
US9242987B2 (en) * 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
CA2797719C (en) 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
US9725425B1 (en) * 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
KR101766194B1 (ko) 2015-08-07 2017-08-10 한국과학기술연구원 RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
AU2016356694B2 (en) 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
MX2021007179A (es) * 2018-12-20 2021-09-28 Ksq Therapeutics Inc Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1).
WO2021146378A1 (en) 2020-01-15 2021-07-22 KSQ Therapeutics, Inc. Compositions of substituted pyrazolopyrimidines and uses thereof
KR20220140732A (ko) 2020-02-14 2022-10-18 케이에스큐 세러퓨틱스 인코포레이티드 유비퀴틴-특이적-프로세싱 프로테아제 1(usp1) 억제제 및 폴리 (adp-리보스) 중합효소(parp) 억제제를 포함하는 치료학적 조합물
WO2022174184A1 (en) 2021-02-15 2022-08-18 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer

Also Published As

Publication number Publication date
KR20230098186A (ko) 2023-07-03
IL302352A (en) 2023-06-01
WO2022094096A1 (en) 2022-05-05
CA3196564A1 (en) 2022-05-05
EP4236958A1 (en) 2023-09-06
CN116615424A (zh) 2023-08-18
TW202233621A (zh) 2022-09-01
JP2023548148A (ja) 2023-11-15
US11718624B2 (en) 2023-08-08
AU2021371305A1 (en) 2023-06-15
US20240034738A1 (en) 2024-02-01
US20220162213A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2023004937A (es) Formas en estado solido de pirazolopirimidinas sustituidas y usos de estas.
CR20220363A (es) Compuestos tricíclicos sustituidos
CR20220312A (es) Compuestos tricíclicos sustituidos
MX2022005053A (es) Inhibidores de peque?as moleculas de mutante g12c de kras.
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
ZA202104423B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CR20210409A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
EP4233865A3 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2023001298A (es) Combinaciones para el tratamiento de cancer.
MX2021012105A (es) Compuestos de pirrol.
WO2023158679A3 (en) Thiostrepton-inspired compounds for treatment of cancer and preparation thereof
MX2023007162A (es) Macrociclos y sus usos.
MX2023000503A (es) Macrociclos y su uso.
MX2011008677A (es) Derivados de pirazolopirimidina triciclicos.
UA106967C2 (uk) Протипухлинні аналоги пептидів, фармацевтична композиція, спосіб одержання сполук та проміжні сполуки
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2022000308A (es) Formulacion de nanoparticulas de inhibidor de bcl-2.
MX2021009206A (es) Terapias contra el cancer.
MX2023007554A (es) Compuesto espirocíclico como inhibidor del homólogo del oncogén viral del sarcoma 2 de rata de kirsten con mutación g12c (kras-g12c).
MX2023004998A (es) Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.